OIS @ ASCRS 2016Barry Cheskin, May 5, 2016

2PowerVision │ FluidVision™ IOL

The FluidVision™ A-IOL Advantage

First true shape changing, fluid-driven IOL

Mimics eye’s natural accommodative process

Creates a continuously variable monofocal

Designed to restore True AccommodationTM

Excellent visual outcomes out to 36 months

3PowerVision │ FluidVision™ IOL

How the FluidVision Lens Works

• When the eye moves to its natural accommodated state, the capsular bag squeezes a tiny amount of fluid (less than a drop) from the haptics at the periphery of the A-IOL into the center

• This inflates the lens, giving near vision

• When the eye attempts to move to its disaccommodated state, the capsular bag squeezes fluid the other way

• This deflates the lens, giving far vision

4PowerVision │ FluidVision™ IOL

Evolution of an Accommodating IOL

Conceptual • Non Optical• Non-foldable• Proof of

concept in blind eyes

• Single Center Study

• Non-foldable• Single Center

Study

• Foldable• Never

released to clinic

• Superseded by Gen 4

FluidVision™• Foldable• PowerJect™

injector (pre-loaded)

• Started with 4.0 mm, moved to 3.5 mm incision

• Single Center and Multicenter Studies

FluidVision 20/20™• Foldable• Nearly twice the

accommodation• Achieve 20/20 across

all distances• Minor mechanical

and optical design changes

• Studies to get underway soon

Gen 0 Gen 1 Gen 2 Gen 3 Gen 4 Gen 5

5PowerVision │ FluidVision™ IOL

Summary of Recent Clinical Studies

Sighted Eyes (monocular)

Single Center PilotEnrollment completed

2013

4.0 mm incision device

26 eyes

Sighted Eyes (monocular)Multi Center

Enrollment completed 2014

4.0 mm incision device,

pre-loaded injector

67 eyes

Sighted Eyes (monocular)Multi Center

Enrollment completed 2015

3.5 mm incision device,

pre-loaded injector

50 eyes

Sighted Eyes (binocular)

Single Center PilotEnrollment completed

2015

4.0 mm incision device

pre-loaded injector

8 eyes

6PowerVision │ FluidVision™ IOL

Excellent, Stable Outcomes from Pilot Study

M1(n=26)

M3(n=26)

M6(n=26)

M12(n=24)

M18(n=19)

M24(n=18)

M36(n=11)

-0.20

-0.10

0.00

0.10

0.20

0.30

0.40

Best Corrected Distance VA

AVG

logM

AR V

A

M1(n=26)

M3(n=26)

M6(n=25)

M12(n=23)

M18(n=17)

M24(n=17)

M36(n=8)

0.00

1.00

2.00

3.00

4.00

AVG Accommodation by Defocus

Diop

ters

• Patients achieved 20/20 or better mean BCDVA

• Patients showed stable intermediate and near visual acuities over 36 months:

- Mean DCIVA of +0.11 logMar

- Mean DCNVA of +0.26 logMar

• The FluidVision AIOL achieves stable results in the capsular bag over time

• All results monocular

7PowerVision │ FluidVision™ IOL

Multi-Center Outcomes Comparable to Pilot

M3 (n=121)

M6 (n=114)

M12 (n=61)

M18 (n=45)

M24

-0.20

-0.10

0.00

0.10

0.20

0.30

0.40

Best Corrected Distance VA

AVG

logM

AR V

A

M3 (n=121)

M6 (n=114)

M12 (n=61)

M18 (n=45)

0.00

1.00

2.00

3.00

4.00AVG Accommodation by Defocus

AVG

logM

AR V

A

• Multi-Center Studies show comparable outcomes to Single Center Pilot Study, including stable intermediate and near visual acuities out to 18 Months

• Decreased incision size to 3.5 mm with improved injector and procedure

• All results monocular

8PowerVision │ FluidVision™ IOL

Proven Subjective Accommodation

Mean Accommodation by Defocus at 1-Month and 12-Month visit

1-month 12-month0.00

1.00

2.00

3.00

4.00

5.00

Binocular Patients (n=8) Monocular Patients (n=26)

Dio

pter

s

Defocus Curve: 12-Month Data

-3-2.5-2-1.5-1-0.500.511.52

-0.3

-0.2

-0.1

5.55111512312578E-17

0.1

0.2

0.3

0.4

0.5

0.6

0.7

Defocus (D)

logM

AR

66 cm 40 cm

Bilaterally implanted subject with mean VA of 20/40 or better through 5.0 D of defocus

• Stable accommodative function over time• Average binocular improvement of >1.0 D

over monocular results

9PowerVision │ FluidVision™ IOL

Proven Objective Accommodation

Average objective accommodation = 1.7D** Average objective accommodation based on 6 month results, Multi-Center (monocular), status March 2016

10PowerVision │ FluidVision™ IOL

Product Development Plans

FluidVision 20/20

3.5 mmIncision

Near visualacuity to 20/20

3.2 mm incision Toric

Post implantadjustment,

2.8 mm incision

11PowerVision │ FluidVision™ IOL

Strategic Alliance Announcement

• Alcon and PowerVision recently entered into a strategic alliance

• Alcon’s investment will fund further development and clinical trials and provide Alcon the option to acquire PowerVision